Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check44 days agoChange DetectedUpdated site revision from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page now displays Revision: v3.4.2, replacing v3.4.1, which is a minor update with no changes to study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check73 days agoChange DetectedThe recruitment/status changed to Completed. The study completion date (Actual) is listed as 2026-01-09, with updates through 2026-01-30 and a new revision (v3.4.1).SummaryDifference0.4%

- Check81 days agoChange DetectedAdded a Show glossary option and updated page metadata to include 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. Removed/changed older labels such as 'Last Update Submitted that met QC Criteria' (capitalization), 'No FEAR Act data', and the older 'Revision: v3.3.4'.SummaryDifference0.2%

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.